Bedaquiline, Pretomanid, and Linezolid for Multidrug-Resistant Tuberculosis Treatment in the United States: A BIG Deal

Clin Infect Dis. 2023 Oct 5;77(7):1063-1064. doi: 10.1093/cid/ciad314.

Authors

Carlos Acuña-Villaorduña^{1

2}, Pranay Sinha^{1

2}

Affiliations

¹ Department of Medicine, Section of Infectious Diseases, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
² Section of Infectious Diseases, Tuberculosis Clinic, Boston Medical Center, Boston, Massachusetts, USA.

PMID: 37249072
DOI: 10.1093/cid/ciad314

No abstract available

Publication types

Editorial
Comment